Delving into the Latest Updates on Ferrous Succinate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Ferrous succinate

Target-

Mechanism

Fe modulators

Therapeutic Areas

Endocrinology and Metabolic DiseaseHemic and Lymphatic DiseasesNervous System Diseases+ [2]

Active Indication

Anemia, Iron-DeficiencyCognitive DysfunctionIschemic Attack, Transient+ [1]

Inactive Indication-

Originator Organization-

Active Organization

Capital Medical UniversityNanjing Jinling Pharmacy Co., Ltd.

Beijing Tiantan Biological Products Corp. Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC4H6FeO4

InChIKeyVAMMNAAZSNNEDJ-UHFFFAOYSA-N

CAS Registry10030-90-7

Iron deficiency is prevalent worldwide, and iron supplementation is a promising strategy to address iron needs of the body. However, traditional oral supplements such as ferrous sulfate, ferrous succinate, and ferrous gluconate are absorbed in the form of ferrous ions, leading to lipid peroxidation and side effects due to other reasons. In recent years, saccharide-iron (III) complexes (SICs) as novel iron supplements have aroused attention for the high iron absorption rate and no gastrointestinal irritation at oral doses. In addition, research on the biological activities of SICs revealed that they also exhibited good abilities in treating anemia, eliminating free radicals, and regulating the immune response. This review focused on the preparation, structural characterization, and bioactivities of these new iron supplements, as promising candidates for the prevention and treatment of iron deficiency.

01 Jul 2024·Indian Pediatrics

Comparative Efficacy of Ferrous, Ferric and Liposomal Iron Preparations for Prophylaxis in Infants

Article

Author: Konuksever, Dilek ; Özbek, Namik Yasar ; Kiliç, Betül Orhan

OBJECTIVEThis study aimed to assess the efficacy of different oral iron preparations prescribed for prevention of iron deficiency anemia in healthy infants.METHODSThis retrospective study enrolled infants aged between 6 and 12 months who were initiated on iron prophylaxis at four months of age. Enrolled children consistently used specific iron preparations (ferrous, ferric or liposomal iron) and had their complete blood counts and serum ferritin levels assessed within the 6-12 month timeframe. Blood values and iron prophylaxis type (ferrous (Fe+2), ferric (Fe+3), liposomal iron) were recorded. Chi-square test was used to compare the hemoglobin and ferritin levels levels between groups. Univariate and multivariate regression analyses assessed the risk of anemia.RESULTSThe study included 371 children (ferrous sulphate - 60, iron hydroxide-polymaltose complex - 137 and liposomal ferric pyrophosphate - 174) with a mean (SD) age 9.1 (1.3) mo. Iron deficiency in different groups were: liposomal iron (46.0%), ferric iron (44.5%), and ferrous iron (5.0%). Mean (SD) serum ferritin levels (µg/L) were higher in the ferrous group [30.1 (10.8)] compared to infants receiving ferric [17.6 (14.50)] and liposomal iron [15.4 (12.1)] (P < 0.001). Mean (SD) hemoglobin levels (g/dL) were significantly higher in the ferrous group [12.4 (0.8)] compared to ferric [11.9 (1.1)] and liposomal iron group [12.0 (1.1)]; P =0.008. Multiple regression analysis showed that ferrous group was associated with a lower risk of iron deficiency [OR (95% CI) 0.04 (0.01-0.15), P < 0.001].CONCLUSIONFerrous iron demonstrated superior efficacy compared to ferric and liposomal iron. Further studies are needed to establish alternative iron preprations in children.

10 Jun 2024·ACS Biomaterials Science & Engineering

H₂S-Powered Nanomotors for Active Therapy of Tumors by Inducing Ferroptosis and Lactate-Pyruvate Axis Disorders

Article

Author: Pan, Min ; Sun, Jiahui ; Wu, Jianming ; Liu, Jin ; Qiao, Weiwei ; Wang, Zhongchao ; Hong, Miaofang ; Gao, Rui ; Mei, Qibing ; Luo, Lei ; Zhong, Yali ; Fu, Renquan ; Xue, Yingli ; Wang, Weixin ; Wang, Yini ; Qiao, Lingyan ; Tong, Fei

Disruption of the symbiosis of extra/intratumoral metabolism is a good strategy for treating tumors that shuttle resources from the tumor microenvironment. Here, we report a precision treatment strategy for enhancing pyruvic acid and intratumoral acidosis to destroy tumoral metabolic symbiosis to eliminate tumors; this approach is based on PEGylated gold and lactate oxidase-modified aminated dendritic mesoporous silica with lonidamine and ferrous sulfide loading (PEG-Au@DMSNs/FeS/LND@LOX). In the tumor microenvironment, LOX oxidizes lactic acid to produce pyruvate, which represses tumor cell proliferation by inhibiting histone gene expression and induces ferroptosis by partial histone monoubiquitination. In acidic tumor conditions, the nanoparticles release H₂S gas and Fe²⁺ ions, which can inhibit catalase activity to promote the Fenton reaction of Fe²⁺, resulting in massive ·OH production and ferroptosis via Fe³⁺. More interestingly, the combination of H₂S and LND (a monocarboxylic acid transporter inhibitor) can cause intracellular acidosis by lactate, and protons overaccumulate in cells. Multiple intracellular acidosis is caused by lactate-pyruvate axis disorders. Moreover, H₂S provides motive power to intensify the shuttling of nanoparticles in the tumor region. The findings confirm that this nanomedicine system can enable precise antitumor effects by disrupting extra/intratumoral metabolic symbiosis and inducing ferroptosis and represents a promising active drug delivery system candidate for tumor treatment.

100 Deals associated with Ferrous Succinate

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Anemia, Iron-Deficiency	CN	Nanjing Jinling Pharmacy Co., Ltd.	01 Jan 1993

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cognitive Dysfunction	Phase 2	CN	Capital Medical University	24 May 2024
Cognitive Dysfunction	Phase 2	-	Beijing Tiantan Biological Products Corp. Ltd.	24 May 2024
Ischemic Attack, Transient	Phase 2	CN	Capital Medical University	24 May 2024
Ischemic Attack, Transient	Phase 2	-	Beijing Tiantan Biological Products Corp. Ltd.	24 May 2024
Stroke	Phase 2	CN	Capital Medical University	24 May 2024
Stroke	Phase 2	-	Beijing Tiantan Biological Products Corp. Ltd.	24 May 2024